Lidiya N. T.
- Country
- Bulgaria
- Department
- Department of Pneumology and Phthisiatrics
Research Overview
- Efficacy and Safety of Early Depemokimab Initiation as Add-on Therapy in Patients with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation
- Evaluation of Budesonide, Glycopyrronium Bromide, and Formoterol Fumarate on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease Patients
- Efficacy, Safety, and Tolerability of Beclometasone Dipropionate, Formoterol Fumarate, and Glycopyrronium Bromide in COPD: A Randomized, Double-Blind Study
Data & Insights
Has run more than one trial at 253 of 672 partner sites.
Specializations
Chronic Obstructive Pulmonary Disease and Type 2 inflammation
Lidiya Nikolcheva-Todorova’s clinical research is strongly centered on chronic obstructive pulmonary disease, including persistent symptoms, exacerbation control, and long-term disease management in patients with inflammatory airway disease.
- COPD symptom control
- Exacerbation prevention
- Type 2 inflammatory pathways
- Long-term respiratory safety
Her work also includes interest in advanced inhaled and biologic approaches for chronic airway disease, with attention to both functional outcomes and sustained tolerability.
Severe Asthma and Eosinophilic Airway Disease
Her trial activity includes asthma with a particular focus on severe eosinophilic asthma, where treatment goals center on reducing exacerbations and improving daily respiratory stability.
- Severe asthma exacerbations
- Eosinophilic airway inflammation
- Maintenance inhaled therapy
- Biologic treatment in asthma
Her clinical interests extend to therapies used alongside standard inhaled regimens, reflecting involvement in both symptom relief and longer-term asthma control.
Influenza and Respiratory Virus Prevention
Another major area of activity is influenza, including vaccine-based prevention, antiviral susceptibility, and protection against seasonal disease in older adults and other at-risk populations.
- Influenza vaccination
- Seasonal influenza A and B
- Antiviral resistance
- Immunogenicity in older adults
Her research landscape also covers broader respiratory virus prevention, with emphasis on reducing illness burden through immunisation and antiviral strategies.
COVID-19 and Severe Viral Lung Infections
Her portfolio includes studies in SARS-CoV-2 (COVID-19) infection and severe viral lung infections, particularly in patients with significant respiratory compromise.
- Hospitalized viral pneumonia
- Supplemental oxygen requirement
- Progression of viral respiratory disease
- COVID-19 treatment
This area reflects clinical involvement in therapies aimed at preventing deterioration in acute viral lung disease and supporting respiratory recovery.
Inflammation-Modulating Respiratory Therapies
Lidiya Nikolcheva-Todorova is also involved in research on emerging respiratory treatments targeting inflammatory control across obstructive lung disease and acute viral illness.
- Biologic therapy in airway disease
- Add-on treatment for obstructive lung disease
- Anti-inflammatory respiratory treatment
- Long-term treatment tolerability
Her clinical trial activity spans both chronic and acute respiratory settings, with interest in therapies designed to modify inflammatory burden and improve respiratory outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.